Acutus Medical (AFIB)
(Delayed Data from NSDQ)
$0.17 USD
0.00 (1.90%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $0.16 -0.01 (-3.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.17 USD
0.00 (1.90%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $0.16 -0.01 (-3.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -3.28% and 14.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 27.14% and 5.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 158.57% and 3.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -1.01% and 29.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aerie (AERI) delivered earnings and revenue surprises of -1.54% and 1.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Acutus Medical, Inc. (AFIB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -8.70% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 5.19% and 6.84%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Acutus Medical, Inc. (AFIB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acutus Medical, Inc. (AFIB) Moves 9.6% Higher: Will This Strength Last?
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 11.00% and 1.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?